<DOC>
	<DOCNO>NCT02287610</DOCNO>
	<brief_summary>The overall objective study ass effectiveness switch immediate-release prednisone ( conventional ) therapy delayed-release prednisone ( RAYOS ) patient moderately severely active Rheumatoid Arthritis ( RA ) , manage accord standard care clinical practice setting .</brief_summary>
	<brief_title>A Non-Interventional Study RAYOS Adult Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Adult Rheumatoid Arthritis ( RA ) participants previously receive immediate release prednisone enrol trial physician consent . Once enter , participant baseline data capture switched delayed-release prednisone follow approximately 12 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Age ≥ 18 general good health ( Investigator discretion ) recent stable medical history relate RA disease activity RA diagnosis ≥ 6 month accord ACR and/or EULAR classification criterion diagnosis active RA Morning stiffness duration least 45 minute study entry RA disease activity define DAS28 ≥ 3.2 study entry Currently receive conventional immediaterelease prednisone ≥ 2.5 milligram ( mg ) every morning previously agree switch RAYOS Willing able sign Informed Consent Form ( ICF ) Patient unwilling participate noninterventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RA</keyword>
	<keyword>Delayed-release prednisone</keyword>
	<keyword>Immediate-release prednisone</keyword>
	<keyword>Non-interventional</keyword>
</DOC>